Introduction/Background Primary Classic Follicular Lymphoma (PCFL) of the female genital tract is a rare entity. Primary genital tract lymphomas accounts for only 1% of cases.

PCFL in this case involves the uterus, ovaries and cervix. It originates from the uncontrolled division of specific types of B-cells known as centrocytes and centroblasts which normally occupy the follicles in the germinal centers of lymphoid tissues.

Methodology This is a case of a 35 year-old, G1P1 (1001) presents with AUB and abdominopelvic mass.

Abdominal examination showed a solid AP mass extending to the level of umbilicus with limited mobility.

Imaging revealed multiple solid multilocular mass occupying the pelvic cavity with moderate color flow.

LEEP was done and revealed Malignant Round Cell Neoplasm and subsequently underwent PFC and total abdominal hysterectomy with bilateral salpingo-oophorectomy. Gross examination of the specimen revealed uterus and ovaries were converted to a solid mass with cystic spaces.

Histopathologic report revealed Mature B Cell Lymphoma (PCFL) of the female reproductive tract confirmed with immunohistochemical stains panel CD 3, CD 20, CD 45 and ER.

Results B Cell Lymphomas are types of lymphomas affecting B cells. 40% are extra nodal. Primary lymphoma involving the female genital tract is uncommon affecting premenopausal women.

Deep biopsy of the lesion is necessary for diagnosis and essential diagnostic criteria of PCFL is the lymphoid proliferation with cytological features of follicle-center cells, focal atypical follicle formation, B-lineage with expression of follicle-center cell markers. IHC are useful for correct diagnosis, as PCFL is difficult to distinguished from benign reactive diseases.

Prognosis depends Ann Arbor Staging System with a 5-year survival rate of 88.6%. Treatment is multimodal. Chemotherapy using R-CHOP regimen which includes rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone.

Conclusion We discussed the case of a Primary Classical Follicular Lymphoma from Reproductive Organs.

Disclosures None.